Evaluating the clinical and cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care

Intensive Care National Audit & Research Centre (ICNARC)0 个研究点目标入组 16,500 人开始时间: 2020年12月8日最近更新: 2024年7月22日

适应症

试验速览

2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38737312/ (added 08/07/2024)

•1. Aged =18 years
•2. Receiving invasive mechanical ventilation in the ICU following an unplanned ICU admission (i.e. not admitted after an elective procedure) OR invasive mechanical ventilation started in the ICU (i.e. the patient was intubated in the ICU)
•3. Receiving supplemental oxygen (fractional inspired concentration of oxygen (FiO2) >0.21) at the time of enrolment

•1. Previously randomised into UK-ROX in the last 90 days
•2. The clinician considers that one study treatment arm is either indicated or contraindicated.
•Removed 20/04/2021:
•A data dictionary will contain relevant examples of conditions where clinicians may exclude patients (at their discretion) because conservative oxygen therapy is either indicated or contraindicated (e.g. chronic lung diseases, receiving hyperbaric oxygen, prior bleomycin exposure, carbon monoxide poisoning).
•Added 22/02/2021:
•3. Currently receiving extracorporeal membrane oxygenation (ECMO)

发起方

Intensive Care National Audit & Research Centre (ICNARC)